89
USA and China are using blood plasma therapy for treatment of COVID-19 victims.Naturally , many in India are asking why India is not using it. Shree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) an Institution of National Importance under the Department of Science and Technology has obtained a go-ahead for taking a bold step to provide innovative treatment to patients suffering from COVID-19 disease.
Technically called “convalescent-plasma therapy”, the treatment aims at using the immune power gained by a recovered person to treat a sick person. Indian council for medical research (ICMR) the top authorising body in India has given approval to the SCTIMST for carrying out the novel treatment.
“We have applied for age cut off to the Drug Controller General of India (DCGI) for permissions for relaxation of the norms for blood donation,” said Dr Asha Kishore Director, SCTIMST.
When a pathogen like novel coronavirus infects, our immune systems produce antibodies. Like the police dogs, the antibodies span out to identify and mark the invading virus. White blood cells attach the identified intruders, and the body gets rid of the infection.
The therapy, like blood transfusion, harvests the antibody from a recovered patient and ingest into a sick person. Helped by the antibody, the immune system mounts robust combat on the virus.
Antibodies are one of the front-line immune response to an infection by a microbe. They are a particular type of proteins secreted by immune cells called B lymphocytes when they encounter an invader, such as a novel coronavirus.
The immune system designs antibodies that are highly specific to each invading pathogen. A particular antibody and its partner virus are made for each other.
Blood is drawn from a person who has recovered from COVID-19 sickness. The serum is separated and screened for virus-neutralizing antibodies.
Convalescent serum, that is the blood serum obtained from one who has recovered from an infectious disease and especially rich in antibodies for that pathogen, is then administered to a COVID-19 patient. The sick acquires passive immunisation.
“Potential donor would be examined before the blood serum is extracted and given to a sick person. First, the swab test must be negative and the potential donor has to be declared as cured. Then the recovered person has to wait for two weeks. Or else the potential donor should be asymptomatic for at least 28 days. Either of the two is mandatory” said Dr Kishore while speaking with India Science Wire.
“Initially we will try in a small number of patients. At present it is permitted as an experimental therapy for restricted use for severely affected patients only. We will be getting the informed consent before they are recruited. This will be conducted as a clinical trial” said Dr Kishore. COVID clinics of five medical college hospitals will be partnering in this study.
This therapy is akin to passive immunization. When a vaccine is administrated, the immune system produces the antibodies. Thus, in a later date, when the vaccinated person is infected by that pathogen, the immune system releases the antibodies and neutralise the infection.
Vaccination provides lifelong immunity. In the case of passive antibody therapy, the effect lasts only up to the time the antibodies injected remain the bloodstream. The protection given is temporary.
The mother transfers antibodies through breast milk to an infant before the child could build her own immunity.
Way back in 1890, Emil von Behring, a German physiologist, discovered that the serum obtained from a rabbit infected with diphtheria was effective in preventing the diphtheria infection. Behring was awarded the first-ever Nobel prize for medicine in 1901.
Antibodies were not known at that time. Convalescent serum therapy was less effective and had substantial side effects. It took many years before the antibody fraction could be separated. Still, the unintended antibodies and impurities caused side effects.
We have effective antibiotics against bacterial infection. However, we do not have effective antivirals. Whenever a new viral outbreak takes places, there are no drugs to treat it. Hence, the convalescent serum has been used during past viral epidemics.
During the outbreak of 2009–2010 H1N1 influenza virus pandemic, patients with an infection requiring intensive care were used. After the passive antibody treatment, the serum-treated individuals showed clinical improvement.
The viral burden reduced, and the death rate could be lowered. The procedure was also useful during the Ebola outbreak in 2018.
With modern blood banking techniques that screen for blood-borne pathogens is robust. It is not difficult to match the blood type of donors and recipients. Therefore the risks of inadvertently transferring known infectious agents or triggering transfusion reactions are low.
“Just as we do in case of blood donation one has to look for the blood groups and Rh compatibility. Only people whose blood group matches can donate or receive blood. The donor will be stringently examined and tested for certain mandatory factors before they will be permitted to donate the blood. They will undergo tests for hepatitis, HIV, malaria, and so on to ensure that they do not pass on a different pathogen to the receiver” said Dr Asha Kishore, Director, SCTIMST.
After the antibody serum is given, it will stay on the recipient for at least three to four days. During this period, the sick person will recover. Research reports from the USA and China indicate that the beneficial effect of transfusion plasma is obtained in the first three to four days and not later.
This therapy is not simple to harness, primarily due to the difficulty of obtaining significant amounts of plasma from survivors. In diseases like COVID-19, where most of the victims are aged, suffering from other medical conditions such as hypertension, diabetes, and so on, not all recovered patients can volunteer to donate blood.
..... .... Login with Google and support us
